Epigenomics Pays Affymetrix $2M in Stock As Part of Dx Deal | GenomeWeb
NEW YORK (GenomeWeb News) - Epigenomics yesterday paid Affymetrix €1.6 million ($2 million) worth of stock as part of the upfront payments the firms agreed to under their diagnostic alliance announced in June, the company said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.